Physician profile
Catherine Rose
NPI 1376696534
$1,424.20
in general payments reported to CMS, 2019-2025
23 companies · $185 in 2025
The $185 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $160 · 2021: $321 · 2022: $240 · 2023: $111 · 2024: $277 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $572.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $185.87 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $171.18 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $154.24 | 2019-2025 | Cequa |
| Abbvie INC. | $120.74 | 2021-2024 | |
| Thea Pharma INC. | $97.95 | 2023-2024 | Iyuzeh |
| Alcon Vision LLC | $86.12 | 2019-2022 | |
| Astellas Pharma US INC | $67.76 | 2019-2021 | |
| Almatica Pharma LLC | $64.81 | 2021-2022 | |
| Abbott Laboratories | $62.41 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $57.07 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $46.41 | 2023-2024 | Miebo, Vyzulta |
| Akorn Operating Company LLC | $44.44 | 2021 | |
| Oyster Point Pharma, INC. | $36.82 | 2023-2024 | Tyrvaya |
| Amgen INC. | $36.79 | 2025 | Tepezza |
| Harrow Eye, LLC | $32.07 | 2024-2025 | Vevye |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $32.04 | 2020-2023 | Tepezza |
| Xeris Pharmaceuticals, INC. | $30.57 | 2022-2023 | Gvoke Hypopen |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.51 | 2020 | |
| Shire North American Group INC | $18.44 | 2019 | |
| Akorn, INC. | $17.20 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.35 | 2022 | |
| Lilly USA, LLC | $13.95 | 2024 | Mounjaro |
| Eyevance Pharmaceuticals LLC | $12.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.